Caroline Diaz
General Counsel chez DOVA PHARMACEUTICALS, INC.
Profil
Caroline Diaz is currently the Director of Regulatory Affairs at Dova Pharmaceuticals, Inc. and the Senior Vice President of Regulatory Affairs at Verona Pharma Plc.
Previously, she held the position of Vice President of Regulatory Affairs at ReViral Ltd.
Ms. Diaz completed her undergraduate degree at Hope College and her graduate degrees at The University of North Carolina at Charlotte and the University of North Carolina at Chapel Hill.
Postes actifs de Caroline Diaz
| Sociétés | Poste | Début |
|---|---|---|
| DOVA PHARMACEUTICALS, INC. | General Counsel | - |
| VERONA PHARMA PLC | General Counsel | 01/10/2021 |
Anciens postes connus de Caroline Diaz
| Sociétés | Poste | Fin |
|---|---|---|
ReViral Ltd.
 ReViral Ltd. BiotechnologyHealth Technology ReViral Ltd. specializes in the areas of virology and antiviral therapies. It offers drugs to treat respiratory synctial virus infection. The company was founded by Neil Matthews and Stuart Cockerill in 2011 and is headquartered in Stevenage, the United Kingdom. | General Counsel | - |
Formation de Caroline Diaz
| Hope College | Undergraduate Degree |
| University of North Carolina at Chapel Hill | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| VERONA PHARMA PLC | Health Technology |
| Entreprise privées | 2 |
|---|---|
ReViral Ltd.
ReViral Ltd. BiotechnologyHealth Technology ReViral Ltd. specializes in the areas of virology and antiviral therapies. It offers drugs to treat respiratory synctial virus infection. The company was founded by Neil Matthews and Stuart Cockerill in 2011 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
Dova Pharmaceuticals, Inc.
 Dova Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Dova Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company, which engages in the acquisition, development and commercialization of drug candidates for rare diseases. It focuses on addressing thrombocytopenia, a disorder characterized by a low blood platelet count. Its drug candidate includes avatrombopag, an orally administered thrombopoietin receptor agonist. The company was founded on March 24, 2016 and is headquartered in Durham, NC. | Health Technology |
